Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790396 | 0.87 | DRD2 (0.39) | DRD2 | |
| SCHEMBL5937197 | 0.86 | SLC6A4 (0.42) | SLC6A4DRD2SIGMAR1 | |
| SCHEMBL6708008 | 0.85 | SLC6A4 (0.40) | SLC6A4DRD2SIGMAR1 | |
| SCHEMBL5899925 | 0.84 | SLC6A4 (0.40) | SLC6A4DRD2 | |
| SCHEMBL5899855 | 0.84 | SLC6A4 (0.38) | SLC6A4DRD2 | |
| SCHEMBL6784310 | 0.84 | HTR1A (0.45) | DRD2 | |
| Hydrochloric Acid SCHEMBL5899865 | 0.84 | SLC6A4 (0.39) | SLC6A4DRD2 | |
| SCHEMBL6664810 | 0.83 | SLC6A4 (0.39) | SLC6A4DRD2 | |
| SCHEMBL5899843 | 0.83 | ADRA1D (0.45) | SLC6A4SIGMAR1 | |
| SCHEMBL6661726 | 0.82 | SLC6A4 (0.37) | SLC6A4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | BOUILLOT ANNE (FR) | 2004-07-29 | — | — | US | disclosed |
| EP-1351937-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055497-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | SLC6A4 969/4885DRD2 152/4885SIGMAR1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.